Brief: FDA And CDC Recommend Pause In Use Of Valneva's Chikungunya Vaccine In Elderly
12/05/2025 07:08
May 12 (Reuters) - Valneva SE VLS.PA: PROVIDES UPDATE ON RECOMMENDED USE OF IXCHIQ® BY ELDERLY INDIVIDUALS IN THE UNITED STATES FDA AND CDC RECOMMEND IXCHIQ USE FOR AGES 18 TO 60 EMA TEMPORARILY SUSPENDS IXCHIQ VACCINE FOR INDIVIDUALS OVER 65 FDA AND CDC RECOMMEND PAUSE IN USE OF VALNEVA'S CHIKUNGUNYA VACCINE IN ELDERLY Source text: ID:nGNX6dFh1l Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587 785 110;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency